Pain Phase 3 Readout Calendar

Industry-sponsored pain trials with primary completion in the next 12 months or last 12 months.

Data last updated July 17, 2026 · source: ClinicalTrials.gov

Pro feature

All areas Oncology Immunology Metabolic CNS Cardiovascular Infectious Disease Respiratory Rare Disease Ophthalmology Dermatology Musculoskeletal RenalPain

Next 6 months

Next 12 months

Results posted

Phase 3 Pain

What you can answer with this page

A confidence-graded calendar of every industry Phase 3 pain trial reading out in the next 12 months — with a per-row staleness flag so you know which completion dates are still credible.

What pain trials are reading out soon?

The "upcoming" section shows industry-sponsored Phase 3 pain trials with primary completion ahead, soonest first, each graded by how credible that date is.

Which pain trials have already read out?

The "recently read out" section shows Phase 3 pain trials whose primary endpoint completed in the last 12 months — results posted, or completed and awaiting topline.

How are these readout dates sourced?

Every date is the ClinicalTrials.gov primary completion date — the only public, structured signal. We grade each by whether it is actual or sponsor-estimated, and by how recently the trial record was updated.

Where can I see readouts for other therapeutic areas?

The full cross-area calendar is on the main readout calendar; this page is the Pain slice of it.

Recently read-out results are free; the upcoming calendar shows a free preview. See the full cross-area calendar → or the Pain landscape →

Recently read out & awaiting topline — Pain

· 6

Phase 3 pain trials whose primary endpoint completed in the last 12 months — results posted, or completed and awaiting topline. Most recent first.

Sponsor	Trial / Asset	Indication	Status	Primary completion	Confidence	NCT
RDC Clinical Pty Ltd	Effect of Maolactin™ FMR on Exercise Recovery, Inflammation and Muscle Comfort in an Otherwise Healthy Population Asset: Maolactin	Chronic Inflammation +3	Completed	Q1 2026 2026-02-16	Completed · awaiting Updated 4mo ago	NCT06444763
Taisho Pharmaceutical Indonesia	Counterpain PXM Versus Diclofenac Versus Piroxicam Asset: Piroxicam plus Counterirritant (brand name Counterpain® PXM).	Ankle Sprain +4	Completed	Q1 2026 2026-02-12	Completed · awaiting Updated 4mo ago	NCT07475663
Laboratorios Silanes S.A. de C.V.	Efficacy and Safety of Etoricoxib/Tizanidine Versus Etoricoxib for Acute Low Back Pain Associated to Muscle Spasm Asset: Etoricoxib + Tizanidine fixed dose	Acute Low-back Pain +1	Completed	Q3 2025 2025-09-26	Completed · awaiting Updated 6mo ago	NCT06863662
Cali Pharmaceuticals LLC	CPL-01 in the Management of Postoperative Pain After Bunionectomy Asset: Local anesthetic injection of CPL-01	Bunion +1	Completed	Q3 2025 2025-09-25	Completed · awaiting Updated 4mo ago	NCT05831449
Cali Pharmaceuticals LLC	Herniorrhaphy for Postoperative Pain Asset: local anaesthetic injection of CPL-01	Hernia, Inguinal +1	Completed	Q3 2025 2025-09-15	Completed · awaiting Updated 3mo ago	NCT05813847
Averitas Pharma, Inc.	Comparison of Qutenza (8% Capsaicin) With a Low-dose Capsaicin for Treatment of Nerve Pain After Surgery Asset: Qutenza (capsaicin) 8% topical system	Post Surgical Neuropathic Pain	Completed	Q3 2025 2025-08-28	Completed · awaiting Updated 3mo ago	NCT04967664

Upcoming pain readouts — next 12 months

· 9

Industry Phase 3 pain trials with primary completion ahead, soonest first — confidence-graded by date type and CT.gov staleness.

Sponsor	Trial / Asset	Indication	Status	Primary completion	Confidence	NCT
Ensysce Biosciences	PF614 Analgesic Activity in Acute Postoperative Pain (PF614-301) Asset: PF614 capsule	Postoperative Pain, Acute	Recruiting	Q3 2026 2026-08 (est.)	Estimated · fresh Updated 6mo ago	NCT06602271
Cali Pharmaceuticals LLC	Phase 3 Bunionectomy Study Asset: CPL-01	Postoperative Pain +1	Not Yet Recruiting	Q4 2026 2026-10-30 (est.)	Estimated · fresh Updated 4mo ago	NCT07490496
AFT Pharmaceuticals, Ltd.	A Study of Combogesic® IV (Intravenous) in Pediatric Patients With Acute Pain Asset: Combogesic® IV (fixed-dose combination containing acetaminophen 10 mg/ml + ibuprofen 3 mg/ml in 100 ml solution for infusion)	Acute Pain	Not Yet Recruiting	Q4 2026 2026-10 (est.)	Estimated · aging Updated 8mo ago	NCT07225634
AFT Pharmaceuticals, Ltd.	A Study of Combogesic® 325 in Adolescent Patients With Moderate to Severe Postoperative Pain Associated With Orthopedic Surgery Asset: Combogesic® tablets	Post Operative Pain, Acute	Not Yet Recruiting	Q4 2026 2026-10 (est.)	Estimated · aging Updated 8mo ago	NCT07225140
Olatec Therapeutics LLC	Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare Asset: Dapansutrile	Acute Gout Flare +6	Recruiting	Q4 2026 2026-12-31 (est.)	Estimated · fresh Updated 4mo ago	NCT05658575
Vertex Pharmaceuticals Incorporated	Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN) Asset: Suzetrigine	Diabetic Peripheral Neuropathic Pain	Active Not Recruiting	Q1 2027 2027-01-25 (est.)	Estimated · fresh Updated 6mo ago	NCT06696443
Noema Pharma AG	An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia. Asset: Basimglurant	Trigeminal Neuralgia	Active Not Recruiting	Q1 2027 2027-02-02 (est.)	Estimated · fresh Updated 6mo ago	NCT05217628
Vertex Pharmaceuticals Incorporated	Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy Asset: Suzetrigine	Diabetic Peripheral Neuropathic Pain	Recruiting	Q2 2027 2027-04-06 (est.)	Estimated · fresh Updated 3mo ago	NCT07231419
Vertex Pharmaceuticals Incorporated	Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy Asset: Suzetrigine	Diabetic Peripheral Neuropathic Pain	Recruiting	Q2 2027 2027-05-31 (est.)	Estimated · fresh Updated 4mo ago	NCT06628908

Unlock 4 more pain readouts · plus filters on the full calendar

Upgrade to Pro

About this calendar

Dates anchor on the ClinicalTrials.gov primary completion date — the only public, structured signal — and are graded by date type (actual vs sponsor-estimated) and how recently the record was updated. Sponsor-estimated dates can slip silently, so treat each as a current target rather than a guarantee. See the full readout calendar for all areas and filters.